Conscio Group is a network of quality science organizations with more than 500 associates committed to ensuring good health for all by improving the safety and reliability of pharmaceuticals and food. In the pharmaceutical industry, Conscio partners with its customers "From Idea to Product"- providing expertise in formulation development, IMP Manufacturing, a broad range of analytical technologies for all phases of development and quality control , clinical development and bioanalytics. In the nutrition industry, we partner with customers along the entire "farm to fork" chain, to provide laboratory services, certification, inspection, training as well as on-site monitoring solutions for hygiene and contaminants.

- Full P+L responsibility for Eurofins Technologies, an International Business Line within Eurofins Scientific focused on providing diagnostic technologies for bioanalytical testing in Food Safety, Environmental Safety, Animal Health and Clincal Diagnostics.- Head of group-wide operational and commercial excellence (Operational best practices, Lean Management, sales processes)- R&D, Manufacturing and Commercial functions across 17 legal entities in North America, Europe, Asia and Australia- Acquired and integrated 15 companies into a global player for diagnostic technologies- Deep expertise in M&A, Operational Excellence, Innovation and commercial expansion- Reporting to Founder and Group CEO Eurofins Scientific is an international life sciences company which provides a unique range ofanalytical testing services to clients across multiple industries. The Group believes it is the worldleader in food, environment, pharmaceutical and cosmetics products testing and in agroscienceCRO services. It is also one of the global independent market leaders in certain testing andlaboratory services for genomics, discovery pharmacology, forensics, advanced material sciencesand for supporting clinical studies. In addition, Eurofins is one of the leading global emergingplayers in specialty clinical diagnostic testing.Eurofins is one of the fastest growing listed European companies. Since its IPO on the Frenchstock exchange in 1997, Eurofins’ sales have increased by 35% each year (in compoundaverage) to over EUR 3.7 billion in 2018.Between the Initial Public Offering on 24 October 1997 (€1.83) and 31 December 2018 (€326.00),Eurofins’ share price has multiplied by 177x, an annual average increase of 28% (against 3% forthe SBF 120, 3% for the CAC 40 and 5% for the S&P 500 over the same period).

Strategic responsibility for Neurosurgery, Neuromodulation and intra-operative imaging portfolioFunctional responsibility for Operations, Customer Service, HR, Purchasing, Sales Operations, CRM, Controlling and ITWith more than 9000 systems at more than 3,800 hospitals in about 100 countries, Brainlab technology helps clinicians treat cancers and disorders of the brain and body. Brainlab is dedicated to increasing cancer survivorship and advancing global access and consistency in treatment.A market-leading technology company with a longstanding dedication to innovation in the fields of surgery and radiosurgery, Brainlab develops, manufactures and markets software-driven medical technology. Core products revolve around information-guided surgery, precision radiation therapy, and information and knowledge sharing that fosters interdisciplinary collaboration. Brainlab technology currently powers treatments in the fields of neurosurgery, radiosurgery/radiotherapy, orthopedics, ENT, CMF, spine, and trauma.

Identification of market and technology trends and opportunities Investment in portfolio companiesInvestor RelationsCorporate wide restructuring projects

Growth Strategy for industrial goods manufacturer